CellGenTech
Yokohama, Japan· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
Japanese biotech developing one-time ex-vivo gene therapies using genetically modified human adipocytes for rare genetic diseases.
Rare DiseasesMetabolic DisordersHematology
Technology Platform
GMAC (Genetically Modified Human Adipocytes) platform involving ex-vivo genetic modification of human adipocytes to express therapeutic proteins for implantation as durable, localized protein factories.
Opportunities
Platform expansion to other monogenic disorders requiring protein/enzyme replacement; potential for partnerships with global pharma companies interested in ex-vivo gene therapy approaches.
Risk Factors
Early clinical validation with small patient populations; manufacturing scalability of personalized adipocyte therapies; competition from established enzyme replacement therapies and other gene therapy modalities.
Competitive Landscape
Competes with traditional enzyme replacement therapies (Sanofi, Takeda) and other gene therapy approaches (BioMarin for hemophilia); differentiated by adipocyte-based delivery platform offering potential for durable, localized protein production.